Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials

Kazuko Hasegawa, Kenji Kochi, Hidenori Maruyama, Osamu Konishi, Shunji Toyoda and Toshinari Odawara

*Correspondence to: Hidenori Maruyama, 6-8, Doshomachi 2-Chome, Chuo-ku, Osaka 541-0045, Japan. Tel.: +81 80 4368 2576; Fax.: +81 6 6203 5733; E-mail: hidenori-maruyama@ds-pharma.co.jp.

INTRODUCTION

Dementia with Lewy bodies (DLB) is the second most common type of dementia in older adults after Alzheimer’s disease, accounting for 10%–15% of all dementia cases [1]. The clinical features of DLB are a progressive cognitive decline accompanied by...
fluctuating cognitive function, visual hallucinations, parkinsonism, and rapid eye movement sleep behavior disorder [2]. A recent revision of recommendations on the clinical diagnosis of DLB delineates the clinical features more clearly from diagnostic biomarkers while providing guidance on how best to establish and interpret these parameters [2].

The pathology of parkinsonism in DLB is similar to that in Parkinson’s disease (PD), with both featuring the loss of dopaminergic neurons in the nigrostriatal pathway and presence of Lewy bodies [3–5]. Major characteristics of parkinsonism in DLB include bradykinesia and rigidity, and less frequently, tremor at rest [3, 5, 6]. Given that these motor symptoms are associated with diminished activities of daily living (ADL), falls, difficulty swallowing, and high financial costs of care [7–12], it is clinically beneficial to improve parkinsonism in patients with DLB. Furthermore, ADL is correlated with quality of life and caregiver burden [11, 13], and improvements in ADL can play an important role in improving overall patient outcomes.

Clinical management of parkinsonism in DLB typically includes levodopa, the standard therapy for PD and commonly administered to patients with DLB. However, patients with DLB appear to be less responsive to levodopa compared with patients with PD, and the risk of exacerbation of psychiatric symptoms remains a dose-limiting factor [3, 14–16]. Current evidence for the management of parkinsonism in DLB is limited [14], and no unified evidence-based management strategy for parkinsonism in DLB has been established to date.

Zonisamide, approved globally for the treatment of epilepsy, has been approved for the treatment of PD in Japan, where it is typically prescribed as adjunctive therapy to levodopa [17–20]. The proposed pharmacologic mechanisms responsible for the anti-parkinsonian activity of zonisamide include both dopaminergic (activation of dopamine synthesis and release [21] and inhibition of monoamine oxidase-B [22]) and non-dopaminergic (blockade of sodium channels [23] and T-type calcium channels [24]) functions. In addition, neuroprotective effects of zonisamide have been reported [25–27].

The clear similarities between PD and DLB [5] and the results of an initial series of cases [28] have indicated that zonisamide might be effective for the treatment of DLB patients with parkinsonism. In phase II [29] and III [30] clinical trials within this patient population, zonisamide was shown to improve parkinsonism, assessed by Unified Parkinson’s Disease Rating Scale (UPDRS) part III total score, with a clear benefit on motor function compared with placebo. Furthermore, no notable differences in the incidence of psychiatric adverse events (AEs) were observed between the zonisamide and placebo groups. Based on these outcomes, zonisamide was approved for the treatment of DLB patients with parkinsonism in Japan. However, some differences in efficacy outcomes were observed between the phase II and III clinical trials. Zonisamide 25 mg did not significantly improve parkinsonism in the phase II trial but improved it significantly in the phase III trial. With respect to cognitive function, zonisamide did not decrease the Mini-Mental State Examination (MMSE) score in the phase II trial, while zonisamide 50 mg significantly decreased the MMSE score compared with placebo in the phase III trial. In addition, the efficacy characteristics of zonisamide in the treatment of DLB patients with parkinsonism, such as the responder proportion and the effect on individual motor symptoms, remain unclear. Furthermore, AEs associated with zonisamide that are significantly more frequent than those observed with placebo are unknown. The differences observed between the above two trials may be attributable to insufficient statistical power to detect changes in some of the parameters. Therefore, we performed a post hoc analysis of pooled data from the phase II and III trials [29, 30] to further examine the efficacy and safety of zonisamide in DLB patients with parkinsonism using a larger sample size. Specifically, regarding efficacy, we aimed to determine whether zonisamide improves symptoms of parkinsonism, particularly, which motor symptoms improve with zonisamide, and whether zonisamide affects cognitive function. Regarding safety, we aimed to evaluate the differences in the incidences of overall and individual AEs between zonisamide and placebo.

MATERIALS AND METHODS

Data pooling for analysis

Data were pooled from the phase II (JapicCTI-122040) and phase III (JapicCTI-152839) trials of zonisamide in patients with DLB conducted in Japan [29, 30]; both trials were conducted in accord with the Declaration of Helsinki, Good Clinical Practice Ordinance and relevant regulations. Efficacy analyses were performed on the modified intention-to-treat populations from the two trials, which included all...
Fig. 1. Patient disposition in the phase II and phase III trials used in the current analysis.

randomized patients who received at least one dose of the investigational product and had both baseline and at least one post-baseline UPDRS part III total scores (efficacy set). For the safety analysis, the safety populations from both trials were combined, which included randomized patients who received at least one dose of investigational product (safety set). The patient disposition for both trials is shown in Fig. 1.

Patients and study design

Patients with probable DLB, diagnosed according to the Clinical Diagnostic Criteria for DLB (third report of the DLB consortium, 2005) [3], were eligible for inclusion in the primary trials. Both trials featured a 4-week run-in period followed by a 12-week treatment period with a double-blind, placebo-controlled, parallel-group, randomized, multicenter trial design. The key inclusion criteria were as follows: age 20–84 years (phase II trial) or 20–89 years (phase III trial); UPDRS part III total score ≥ 10; MMSE score 10–26 (phase II trial); and treatment with levodopa/decarboxylase inhibitor combination therapy for ≥ 12 weeks prior to screening, with the dose and regimen unchanged in the 2 weeks immediately prior to screening. In the phase III trial, patients with an MMSE score of < 10 were excluded. In the 4-week single-blind run-in period, all patients received placebo once daily to exclude a subsequent placebo effect. In the treatment period, patients were randomized 1:1:1 to zonisamide (25 or 50 mg) or placebo in a double-blind manner.

Outcomes

The key outcome for the efficacy of zonisamide against parkinsonism in DLB in this analysis was the change from baseline at week 12 in UPDRS part III total score. To reduce inter-/intra-rater variability, training was conducted prior to the trial start. A more detailed analysis of the effects of zonisamide on the following four motor symptoms [31] was also performed: tremor (items 20, 21), rigidity (item 22), bradykinesia (items 23–26, 31), and postural instability/gait disturbance (PIGD) (items 29, 30). For each individual motor symptom, patients with zero or missing values throughout the trial were excluded from the analysis. Responders were determined based on a ≥ 10%, ≥ 20%, or ≥ 30% reduction from baseline in UPDRS part III total score at week 12, in reference to previous reports [16, 32] where missing values were imputed using the last observation carried forward (LOCF) method. Other efficacy outcomes were the change from baseline at week 12 (LOCF) in the Neuropsychiatric Inventory-10 (NPI-10) score [33], representing the behavioral and psychological symptoms of dementia (BPSD) rating scale; and in the MMSE score [34], representing cognitive function. Safety outcomes included the occurrence of AEs during the treatment period in each trial, coded according to the Medical Dictionary for Regulatory Activities, Japanese version, v19.1.

Statistical analysis

All statistical analyses were performed using one-stage meta-analysis methods with individual patient data. Differences in patient demographics and clinical characteristics at baseline among the placebo and zonisamide 25 mg and 50 mg groups were analyzed using the Cochran–Mantel–Haenszel test stratified with trial for categorical variable and analysis of variance with trial as the fixed effect for continuous variables. Efficacy against parkinsonism was assessed using a mixed-effect model for repeated measures among the placebo and zonisamide 25 mg and 50 mg groups with treatment group and trial as the fixed effects and baseline value as a covariate. An unstructured covariance matrix was assumed, and the degree of freedom was estimated using Kenward–Roger’s approximation. p-values for the proportion of responders were calculated using logistic regression analysis with Firth’s penalized likelihood approach, with treatment group and trial as fixed effects and baseline value as a covariate. Statistical differences in MMSE and NPI-10 score changes between the zonisamide and placebo groups were evaluated by analysis of covariance with treatment group and trial as the fixed effects.
and baseline value as a covariate. Interaction $p$-values were calculated to evaluate the heterogeneity between the trials and were added to each original model. Statistical differences in the incidence of AEs between the zonisamide and placebo groups were analyzed using the Mantel–Haenszel test stratified by trial as a fixed effect. All statistical analyses were carried out at a two-sided significance level of 5%. No multiplicity adjustment for multiple treatment groups, outcomes, or visits was performed. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).

**RESULTS**

**Patient demographics and baseline clinical characteristics**

The efficacy set comprised 498 subjects (55.6% male) with a mean age of 76.6 years, mean DLB

| Table 1 | Patient demographics and clinical characteristics at baseline |
|---------|------------------------------------------------------------|
|         | Total (N = 498) | Placebo (N = 173) | 25 mg (N = 165) | 50 mg (N = 160) | $p^*$ |
| Sex, male |                |                  |               |               |      |
| Mean     | 76.6 ± 6.7     | 76.2 ± 7.1       | 76.4 ± 6.6    | 77.1 ± 6.4    | 0.422 |
| Range    | 55–89          | 56–89            | 55–89         | 59–88         |      |
| ≥65      | 472 (94.8)     | 161 (93.1)       | 157 (95.2)    | 154 (96.3)    | 0.427 |
| ≥75      | 320 (64.3)     | 108 (62.4)       | 105 (63.6)    | 107 (66.9)    | 0.688 |
| Disease duration, y |
| DLB     | 1.4 ± 1.7 (n = 497) | 1.5 ± 1.6       | 1.4 ± 1.8     | 1.4 ± 1.6 (n = 159) | 0.943 |
| Motor dysfunction | 3.0 ± 2.5 (n = 495) | 3.0 ± 2.7 (n = 171) | 3.0 ± 2.6 (n = 164) | 3.0 ± 2.3 | 0.993 |
| Dementia | 3.7 ± 2.6 (n = 493) | 3.7 ± 2.6 (n = 172) | 3.7 ± 2.6 (n = 163) | 3.6 ± 2.6 (n = 158) | 0.935 |
| DLB core features |
| Fluctuating cognition | 334 (67.1) | 114 (65.9) | 110 (66.7) | 110 (68.8) | 0.851 |
| Visual hallucination | 297 (59.6) | 101 (58.4) | 97 (58.8) | 99 (61.9) | 0.776 |
| Parkinsonism | 498 (100.0) | 173 (100.0) | 165 (100.0) | 160 (100.0) |      |
| DLB suggestive features |
| Rapid eye movement | 235 (47.2) | 87 (50.3) | 80 (48.5) | 68 (42.5) | 0.336 |
| Sleep behavior disorder | 55 (11.0) | 17 (9.8) | 20 (12.1) | 18 (11.3) | 0.748 |
| Severe neuroleptic sensitivity |      |      |      |      |      |
| Concomitant drugs |
| Baseline levodopa dose, mg/day | 262 ± 153 | 257 ± 154 | 256 ± 159 | 273 ± 147 | 0.510 |
| Baseline levodopa-equivalent dose, mg/day | 295 ± 195 | 294 ± 209 | 291 ± 203 | 300 ± 171 | 0.923 |
| MAO-B inhibitor | 20 (4.0) | 7 (4.0) | 7 (4.2) | 6 (3.8) | 0.966 |
| Amantadine | 25 (5.0) | 6 (3.5) | 10 (6.1) | 9 (5.6) | 0.497 |
| Dopamine agonist | 77 (15.5) | 27 (15.6) | 25 (15.2) | 25 (15.6) | 0.995 |
| A2A receptor antagonist | 8 (1.6) | 5 (2.9) | 2 (1.2) | 1 (0.6) | 0.213 |
| Droxidopa | 21 (4.2) | 4 (2.3) | 6 (3.6) | 11 (6.9) | 0.107 |
| Anti-cholinergic drug | 7 (1.4) | 2 (1.2) | 1 (0.6) | 4 (2.5) | 0.330 |
| COMT inhibitor | 24 (4.8) | 13 (7.5) | 5 (3.0) | 6 (3.8) | 0.120 |
| Anti-dementia drug | 361 (72.5) | 122 (70.5) | 125 (75.8) | 114 (71.3) | 0.500 |
| Donepezil | 260 (52.2) | 82 (47.4) | 85 (51.5) | 93 (58.1) | 0.136 |
| Memantine | 54 (10.8) | 20 (11.6) | 20 (12.1) | 14 (8.8) | 0.581 |
| Rivastigmine | 48 (9.6) | 18 (10.4) | 21 (12.7) | 9 (5.6) | 0.090 |
| Galantamine | 37 (7.4) | 15 (8.7) | 13 (7.9) | 9 (5.6) | 0.547 |
| Yosukansan† | 95 (19.1) | 35 (20.2) | 31 (18.8) | 29 (18.1) | 0.891 |
| Other central nervous system drugs | 207 (41.6) | 68 (39.3) | 74 (44.8) | 65 (40.6) | 0.579 |

Scores at baseline

| UPDRS part III total | 31.5 ± 11.6 | 30.8 ± 10.6 | 32.3 ± 12.5 | 31.6 ± 11.8 | 0.471 |
| MMSE | 21.6 ± 5.2 | 22.1 ± 5.2 | 21.0 ± 5.7 | 21.8 ± 4.7 | 0.180 |
| NPI-10 | 6.8 ± 8.7 | 6.7 ± 8.3 | 7.2 ± 10.2 | 6.5 ± 7.5 | 0.743 |

Data are reported as mean ± standard deviation or n (%). *Analysis of variance for continuous variables and Cochran–Mantel–Haenszel test for categorical variables. †Traditional Japanese herbal medicine. A2A, adenosine A2A; COMT, catechol-O-methyltransferase; DLB, dementia with Lewy bodies; MAO-B, monoamine oxidase B; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory; UPDRS, Unified Parkinson’s Disease Rating Scale.
duration of 1.4 years, and mean levodopa dose of 262 mg/day (Table 1). The safety set comprised 508 subjects (Fig. 1). In the efficacy set, the mean baseline scores of the UPDRS part III total, MMSE, and NPI-10 were 31.5, 21.6, and 6.8, respectively. No differences in baseline parameters were observed among the three treatment groups (Table 1). At baseline, the number of subjects with existing tremor,
particularly tremor at rest, was smaller than that observed for other symptoms or items (Table 2). In addition, the scores for “attention and calculation” and “drawing” in MMSE were relatively lower than those for other items (Table 2).

**Effect on parkinsonism**

Zonisamide significantly decreased the UPDRS part III total score compared with placebo, with no significant difference in score change observed between the zonisamide 25 mg and 50 mg groups (Fig. 2A). Zonisamide significantly improved individual motor symptom scores at week 12 for tremor (25 mg and 50 mg), rigidity (50 mg), and bradykinesia (25 mg and 50 mg) compared with placebo. No significant change in PIGD was observed in either zonisamide group (Fig. 2B). The score changes from baseline at week 12 in UPDRS part III items are shown in Supplementary Figure 1A.

The responder proportions (defined as a reduction in UPDRS part III total score ≥ 10% from baseline) at week 12 (LOCF) were 61.2% (p < 0.001 versus placebo) for zonisamide 25 mg, 55.0% (p = 0.002) for zonisamide 50 mg, and 37.6% for placebo (Fig. 2C), indicating a significant effect for both doses of zonisamide compared with placebo. In responders, the score changes in UPDRS part III total score from baseline at week 12 (LOCF) were –8.0 (0.5) (least squares mean [standard error]), –9.4 (0.5), and –8.3...
Fig. 3. Effect of zonisamide on cognitive function as measured by change from baseline at week 12 in MMSE total score (A), and on BPSD as measured by change from baseline at week 12 in NPI-10 total score (B). LS means (SE) and p-values for change from baseline were calculated using an ANCOVA model with treatment group and trial as fixed effects, and baseline score as covariate. Heterogeneity between the trials was evaluated using p-value for trial-by-treatment interaction, which was added to the original ANCOVA model. ANCOVA, analysis of covariance; BPSD, behavioral and psychological symptoms of dementia; LS mean, least-squares mean; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory; SE, standard error; ZNS, zonisamide.

(0.6) for zonisamide 25 mg, zonisamide 50 mg, and placebo, respectively. The responder proportions by other responder criteria (defined as a reduction in UPDRS part III total score ≥ 20% or ≥ 30% from baseline) are shown in Fig. 2C.

Effect on cognitive function

No significant difference in the change from baseline at week 12 in MMSE score was observed between the zonisamide groups and placebo (Fig. 3A). The score changes from baseline at week 12 in the MMSE individual items are shown in Supplementary Figure 1B.

Effect on BPSD

No significant difference in the change from baseline at week 12 in NPI-10 score was observed between the zonisamide and placebo groups (Fig. 3B). The score changes from baseline at week 12 in the NPI-10 individual items are shown in Supplementary Figure 1C.

Safety

Overall AEs are shown in Table 3. The incidence of AEs was 48.0%, 47.0%, and 57.8% in the placebo, zonisamide 25 mg, and 50 mg groups, respectively, with no significant differences observed between the zonisamide and placebo groups. With respect to the incidence of common AEs reported among the three treatment groups, decreased appetite was shown to have an increased frequency in the zonisamide 50 mg group compared with placebo, but for other AEs, no differences were observed between zonisamide and placebo (Table 3). The incidence of AEs classified as neurologic or psychiatric is shown in Table 4.

DISCUSSION

In the present analysis, the characteristics of the patient population showed similarities to those in previous studies on DLB patients [6, 35, 36], such as a relatively low prevalence of tremor (particularly tremor at rest) and relatively low MMSE item scores of “attention and calculation” and “drawing” (indicating deficits in attention, executive function, and visuoperceptual ability). These characteristics are considered to represent the typical symptomatic features of DLB. However, in this analysis, a lower NPI-10 score was observed compared with previous studies on DLB patients [7, 36]. The difference may be associated with the inclusion criteria “UPDRS part III total score ≥ 10” and primary endpoint “the change from baseline at week 12 in UPDRS part III total score” in the primary trials.

Regarding whether the zonisamide 25 and 50 mg groups had improved symptoms of parkinsonism, and which motor symptoms were improved, in our analysis, zonisamide in both groups was shown to improve symptoms of parkinsonism, particularly bradykinesia and tremor (motor symptoms), with small differences in efficacy on parkinsonism observed between the 25 mg and 50 mg groups. Furthermore, the proportion of responders and changes in score among responders (≥ 10% reduction in UPDRS part III total score) who received zonisamide were comparable to those reported in a previous study of dopaminergic treat-
Table 3

Incidence of adverse events (overall and common adverse events)

|                          | Placebo (N=179) | 25 mg (N=168) | Zonisamide (N=161) | Total (N=329) |
|--------------------------|-----------------|---------------|---------------------|---------------|
|                          | n (%)           | n (%)         | RR [95% CI]        | p             | n (%)           | RR [95% CI] | p             |
| Any AEs                  | 86 (48.0)       | 79 (47.0)     | 1.0 [0.8–1.2]      | 0.846         | 93 (57.8)       | 1.2 [1.0–1.5] | 0.069         | 172 (52.3) | 1.1 [0.9–1.3] | 0.362 |
| Common AEs*              |                 |               |                     |               |                 |               |               |               |
| Nasopharyngitis          | 11 (6.2)        | 12 (7.1)      | 1.2 [0.5–2.6]      | 0.695         | 16 (9.9)        | 1.6 [0.8–3.4] | 0.200         | 28 (8.5)   | 1.4 [0.7–2.7] | 0.336 |
| Appetite decreased       | 2 (1.1)         | 6 (3.6)       | 0.7 [0.7–15.9]     | 0.149         | 11 (6.8)        | 6.2 [1.4–27.6] | 0.018         | 17 (5.2)   | 4.6 [1.1–20.0] | 0.039 |
| Contusion                | 10 (5.6)        | 9 (5.4)       | 1.0 [0.4–2.3]      | 0.943         | 3 (1.9)         | 0.3 [0.1–1.2] | 0.095         | 12 (3.7)   | 0.7 [0.3–1.5] | 0.318 |
| Weight decreased         | 0 (0.0)         | 3 (1.8)       | 4.3 [0.5–38.4]     | 0.191         | 6 (3.7)         | 7.9 [1.0–63.3] | 0.050         | 9 (2.7)    | 5.6 [0.7–43.1] | 0.099 |
| Fall                     | 4 (2.2)         | 3 (1.8)       | 0.8 † [0.2–3.3]    | 0.789 †       | 5 (3.1)         | 1.3 [0.4–4.2] | 0.644         | 8 (2.4)    | 1.0 [0.3–2.8] | 0.953 |
| Somnolence               | 3 (1.7)         | 6 (3.6)       | 2.2 [0.5–8.6]      | 0.279         | 2 (1.2)         | 0.8 [0.1–4.5] | 0.762         | 8 (2.4)    | 1.5 [0.4–5.5] | 0.574 |
| Diarrhea                 | 1 (0.6)         | 3 (1.8)       | 2.1 [0.4–11.4]     | 0.378         | 3 (1.9)         | 2.2 [0.4–11.9] | 0.352         | 6 (1.8)    | 1.9 [0.4–9.1] | 0.414 |
| Back pain                | 2 (1.1)         | 4 (2.4)       | 1.8 [0.4–7.2]      | 0.432         | 2 (1.2)         | 1.1 [0.2–5.4] | 0.896         | 6 (1.8)    | 1.3 [0.3–4.8] | 0.723 |
| Pneumonia                | 1 (0.6)         | 3 (1.8)       | 2.1 [0.4–11.4]     | 0.378         | 2 (1.2)         | 1.9 † [0.2–13.9] | 0.549 †      | 5 (1.5)    | 1.6 [0.3–8.0] | 0.547 |
| Dental caries            | 2 (1.1)         | 5 (3.0)       | 2.1 [0.5–8.3]      | 0.279         | 0 (0.0)         | 0.2 † [0.0–4.6] | 0.330 †      | 5 (1.5)    | 1.1 [0.3–4.3] | 0.896 |

For cells with zero frequency, the value 0.5 was added (Woolf continuity correction). Adjusted RR (95% CI) and p-values versus placebo group were calculated using the Mantel–Haenszel method, stratified by trial as a fixed effect. *Ten most common AEs in the zonisamide total group. †Unadjusted RR (95% CI) and p-values were calculated using Wald’s method if the RR was not calculated in either of the trials. AE, adverse event; CI, confidence interval; RR, risk ratio.
Table 4
Common neurologic and psychiatric adverse events

| Common neurologic and psychiatric AEs† | Placebo (N = 179) | 25 mg (N = 168) | 50 mg (N = 161) | Total (N = 329) |
|--------------------------------------|------------------|-----------------|-----------------|-----------------|
| n (%)                                | n (%)            | n (%)           | n (%)           | n (%)           |
| Somnolence                           | 3 (1.7)          | 6 (3.6)         | 2 (1.2)         | 8 (2.4)         |
| Hallucination                        | 1 (0.6)          | 1 (0.6)         | 2 (1.2)         | 3 (0.9)         |
| Psychiatric symptom†                 | 2 (1.1)          | 2 (1.2)         | 1 (0.6)         | 3 (0.9)         |
| Insomnia                             | 1 (0.6)          | 2 (1.2)         | 1 (0.6)         | 3 (0.9)         |
| Dizziness                            | 1 (0.6)          | 2 (1.2)         | 0 (0)           | 2 (0.6)         |
| Dysgeusia                            | 0 (0)            | 2 (1.2)         | 0 (0)           | 2 (0.6)         |
| Delusion                             | 2 (1.1)          | 0 (0)           | 0 (0)           | 0 (0)           |

*In ≥1% of patients in either group. †Aggravation of existing symptoms. AEs, adverse events.

ment in patients with DLB who received levodopa [15, 16]. Additionally, subgroup analysis among populations by severity of cognitive impairment or BPSD and selected baseline factors showed a reduction in UPDRS part III total scores in many of the patient populations receiving zonisamide (Supplementary Figures 2 and 3). Based on these results, further studies are expected to clarify the details of zonisamide efficacy. Regarding the effect of zonisamide on parkinsonism in patients with DLB, the proportion of responders with ≥30% reduction in UPDRS part III total score was lower than that reported in PD patients from previous studies [17, 18], and similar results were observed in the levodopa study [15].

With respect to the effect of zonisamide on cognitive function, no significant difference was observed between zonisamide (either dose) and placebo on the change in MMSE score. This finding differed from the outcome observed in the phase III trial, where zonisamide 50 mg significantly decreased the MMSE score compared with placebo [30]. Furthermore, in the analysis of the MMSE items and the subgroup analysis among patients with severe cognitive impairment, no differences in MMSE score change were observed between the zonisamide 25 mg or 50 mg groups and the placebo group (Supplementary Figures 1 and 2). These findings, alongside the low frequency of cognitive AEs, indicate that zonisamide does not worsen cognitive function (and also does not improve cognitive impairment).

Regarding the effect of zonisamide on BPSD, no difference in NPI-10 score was observed for either dose of zonisamide versus placebo. Furthermore, in the analysis of the NPI-10 items and the subgroup analysis among patients with severe BPSD, no differences in NPI-10 score change were observed between the zonisamide 25 mg or 50 mg groups and the placebo group (Supplementary Figures 1 and 2). Taken together with the low frequency of psychiatric AEs reported in the two trials, it appears that zonisamide does not worsen BPSD in patients with DLB (and also does not improve BPSD), in contrast to a previous study, which reported an association between levodopa and increased risk of psychiatric AEs in DLB patients [16].

A low incidence of each AE was observed among patients treated with zonisamide in the present study. With the exception of decreased appetite in patients receiving zonisamide 50 mg, the incidence of AEs did not differ between either zonisamide group and placebo. In addition to the low frequency of AEs related to cognitive function and BPSD discussed above, the incidence of other AEs related to characteristic symptoms of DLB, such as autonomic dysfunction [2], was also low, supporting the safety of zonisamide in the current study population.

When evaluating the differences between the two doses of zonisamide, our findings show that the change in UPDRS part III total score was greater in the 50 mg group versus the 25 mg group; however, the difference was not statistically significant, suggesting no difference in efficacy. Regarding safety, although there was no significant difference in the overall incidence rate of adverse events, that in the 50 mg group was slightly higher than that in the 25 mg group, and the incidence rate of decreased appetite was significantly higher in the 50 mg group versus the placebo group. These findings suggest that the recommended dose of zonisamide for DLB patients with parkinsonism is 25 mg.

The present study had some limitations, including the post hoc study design and the inclusion of only Japanese patients, which limits the generalizability of the results. Furthermore, the trials enrolled participants from essentially the same patient population using the same inclusion/exclusion criteria, and the
12-week treatment periods were relatively short. Future studies with longer duration in a broader patient population are therefore required, and real-world study data may also contribute to determining the actual benefits of zonisamide to patients and caregivers.

In conclusion, the outcomes of this post hoc analysis indicate that zonisamide as adjunct therapy to levodopa is efficacious for the treatment of parkinsonism with DLB, particularly the management of bradykinesia, tremor, and rigidity. Importantly, exacerbation of psychiatric symptoms, which is typically associated with levodopa use, was not observed. Zonisamide was shown to be well tolerated in patients with DLB with parkinsonism, with no new safety signals identified in the present analysis.

ACKNOWLEDGMENTS

The authors thank Ian McKeith, MD, BS, FRCPsych, FRSB, FMedSci from Newcastle University, Jennifer G. Goldman, MD, MS from Northwestern University, Shirley Ryan from AbilityLab, Miho Murata, MD, PhD from National Center of Neurology and Psychiatry (former institute), and Kenji Kosaka, MD, PhD from Shonan Inaho Clinic for providing suggestions on the post hoc analysis and interpretation of the data. The authors also thank Masaaki Tagawa, PhD, who is a member of Sumitomo Dainippon Pharma Co., Ltd. for providing support during the manuscript preparation, and Clare Cox, PhD, of Edanz Evidence Generation for providing medical writing support, which was funded by Sumitomo Dainippon Pharma Co., Ltd. This study was funded by Sumitomo Dainippon Pharma Co., Ltd. As Kenji Kochi, Hidenori Maruyama, Osamu Konishi, and Shunji Toya are employees of Sumitomo Dainippon Pharma Co., Ltd., the funding source had a role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript.

Authors’ disclosures available online (https://www.j-alz.com/manuscript-disclosures/20-0893r1).

SUPPLEMENTARY MATERIAL

The supplementary material is available in the electronic version of this article: https://dx.doi.org/10.3233/JAD-200893.

REFERENCES

[1] McKeith IG, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos Machado J, O’Brien J, Playfer J (2004) Dementia with Lewy bodies. Lancet Neurol 3, 19-28.
[2] McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A (2017) Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89, 88-100.
[3] McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65, 1863-1872.
[4] Siepel FJ, Dalen I, Grüner R, Boooj J, Brønnick KS, Buter TC, Aarsland D (2016) Loss of dopamine transporter binding and clinical symptoms in dementia with Lewy bodies. Mov Disord 31, 118-125.
[5] Louis ED, Klatka LA, Liu Y, Fahn S (1997) Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson’s disease. Neurology 48, 376-380.
[6] Burn DJ, Rowan EN, Minett T, Sanders J, Myint P, Richardson J, Thomas A, Newby J, Reid J, O’Brien JT, McKeith IG (2003) Extrapyramidal features in Parkinson’s disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study. Mov Disord 18, 884-889.
[7] McKeith IG, Rowan E, Askew K, Naidu A, Allan L, Barnett N, Lett D, Mosimann UP, Burn D, O’Brien JT (2006) More severe functional impairment in dementia with Lewy bodies than Alzheimer disease is related to extrapyramidal motor dysfunction. Am J Geriatr Psychiatry 14, 582-588.
[8] Ballard CG, Shaw F, Lowery K, McKeith I, Kenny R (1999) The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer’s disease. Dement Geriatr Cogn Disord 10, 97-103.
[9] Shinagawa S, Adachi H, Toyoda Y, Morii T, Matsumoto I, Fukuhara R, Ikeda M (2009) Characteristics of eating and swallowing problems in patients who have dementia with Lewy bodies. Int Psychogeriatr 21, 520-525.
[10] Murman DL, Kuo SB, Powell MC, Colenda CC (2003) The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies. Neurology 61, 944-949.
[11] Boström F, Jönsson L, Minthon L, Londos E (2007) Patients with dementia with Lewy bodies have more impaired quality of life than patients with Alzheimer disease. Alzheimer Dis Assoc Disord 21, 150-154.
[12] Leggett AN, Zarit S, Taylor A, Galvin JE (2010) Stress and burden among caregivers of patients with Lewy body dementia. Gerontologist 51, 76-85.
[13] Svendsboe E, Terum T, Testad I, Aarsland D, Ulstein D, Ulstein I, Corbett A (2016) Caregiver burden in family carers of people with dementia with Lewy bodies and Alzheimer’s disease. Int J Geriatr Psychiatry 31, 1075-1083.
[14] Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, Cambridge V, Mason J, Thomas A, O’Brien JT (2015) Pharmacological management of Lewy body dementia: A systematic review and meta-analysis. Am J Psychiatry 172, 731-742.
[15] Molloy S, McKeith IG, O’Brien JT, Burn DJ (2005) The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 76, 1200-1203.

[16] Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT (2008) Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord 23, 2248-2250.

[17] Murata M, Hasegawa K, Kanazawa I, Japan Zonisamide on PD Study Group (2007) Zonisamide improves motor function in Parkinson disease: A randomized, double-blind study. Neurology 68, 45-50.

[18] Murata M, Hasegawa K, Kanazawa I, Shirakura K, Kochi K, Shimazu R, Zonisamide PD Study Group (2016) Randomized placebo-controlled trial of zonisamide in patients with Parkinson’s disease. Neurol Clin Neurosci 4, 10-15.

[19] Murata M, Hasegawa K, Kanazawa I, Fukasaka J, Kochi K, Shimazu R, Japan Zonisamide on PD Study Group (2015) Zonisamide improves wearing-off in Parkinson’s disease: A randomized, double-blind study. Mov Disord 30, 1343-1350.

[20] Fox SH, Katzschlager R, Lim SY, Barton B, de Bie RMA, Seppi K (2018) International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33, 1248-1266.

[21] Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, Fukushima Y (1995) Effects of zonisamide on dopaminergic system. Epilepsy Res 22, 193-205.

[22] Uemura MT, Asano T, Hikawa R, Yamakado H, Takahashi R (2017) Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity. Neurosci Res 124, 25-32.

[23] Murata M (2004) Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson’s disease. Curr Pharm Des 10, 687-693.

[24] Miwa H, Koh J, Kajimoto Y, Kondo T (2011) Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats. Pharmacol Biochem Behav 97, 656-659.

[25] Ikeda K, Yanagihashi M, Miura K, Ishikawa Y, Hirayama T, Takazawa T, Kano O, Kawabe K, Mizumura N, Iwasaki Y (2018) Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study. J Neurol Sci 391, 5-9.

[26] Hirayama M, Minato T, Maeda T, Nakamura T, Katsuno M (2017) Efficacy of a novel drug, zonisamide, in the modulation of oxidative stress in Parkinson’s disease. Neurol Clin Neurosci 5, 49-54.

[27] Terada T, Yokokura M, Yoshikawa E, Futatsubashi M, Kono S, Konishi T, Miyajima H, Hashizume T, Ouchi Y (2016) Extrastriatal spreading of microglial activation in Parkinson’s disease: A positron emission tomography study. Ann Nucl Med 30, 579-587.

[28] Odawara T, Shiozaki K, Togo T, Hirayasu Y (2010) Administration of zonisamide in three cases of dementia with Lewy bodies. Psychiatry Clin Neurosci 64, 327-329.

[29] Murata M, Odawara T, Hasegawa K, Iiyama S, Nakamura M, Tagawa M, Kosaka K (2018) Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized, double-blind phase 2 study. Neurology 90, e664-e672.

[30] Murata M, Odawara T, Hasegawa K, Kajiwara R, Takeuchi H, Tagawa M, Kosaka K (2020) Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial. Parkinsonism Relat Disord 76, 91-97.

[31] Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E, LARGO Study Group (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO). Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial. Lancet 365, 947-954.

[32] Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ (2010) The clinically important difference on the unified Parkinson’s disease rating scale. Arch Neurol 67, 64-70.

[33] Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.

[34] Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.

[35] Petrova M, Mehrabian-Spasova S, Aarsland D, Raycheva M, Traykov L (2015) Clinical and neuropsychological differences between mild Parkinson’s disease dementia and dementia with Lewy bodies. Dement Geriatr Cogn Dis Extra 5, 212-220.

[36] Mori E, Ikeda M, Nakagawa M, Miyagishi H, Kosaka K (2016) Pretreatment cognitive profile likely to benefit from donepezil treatment in dementia with Lewy bodies: Pooled analyses of two randomized controlled trials. Dement Geriatr Cogn Dis 42, 58-68.